Lowering the USPSTF smoking pack-year lung cancer screening criteria to a minimum 20-pack-year history may increase the number of African American smokers who are screened.
For dual users, restrictive regulations may result in increased combustible cigarette use, lower e-cig use.
Residential exposure linked to AH, reduced HDL cholesterol for individuals living in multistory houses.
As primary care clinicians are on the front lines of care for patients with COPD, they should educate them on the disease process, medication regimens, and nonpharmacologic treatments.
Nearly 50% of tobacco and vape shops surveyed did not follow FDA regulations in checking identification for persons younger than 27 years.
A mean nocturnal respiratory rate of ≥16 breaths per minute was an independent predictor of long-term cardiovascular and all-cause mortality among community-dwelling older men and women.
The safety and efficacy of direct oral anticoagulants were associated with significant overall reductions in mortality in venous thromboembolism compared with observation alone.
The novel Fujifilm SILVAMP TB LAM assay offers superior diagnostic sensitivity while also maintaining specificity, compared with standard assay.
Updated recommendation calls on primary care physicians to prevent tobacco use among children.
Symdeko previously approved for patients ≥12 years with cystic fibrosis and certain genetic mutations.
Prevalence of COPD higher in southeastern and Appalachian states, regardless of smoking status.
Likelihood of working higher if symptoms less severe and on illness onset date vs subsequent days.
The DYNAGITO trial investigated the effectiveness of dual bronchodilation with fixed-dose tiotropium/olodaterol for reducing exacerbations of COPD.
Results from a cross-sectional study found that among expectant mothers who smoked cigarettes before pregnancy, the probability of preterm birth was reduced following smoking cessation.
Larger peripheral total pulmonary vascular volume associated with long-term exposure to black carbon.
Substantial contribution seen to burden of diseases including asthma, COPD, chronic bronchitis, fibrosis.
With 1 year of use, improvements seen in asthma outcomes.
Drug previously approved for treatment of complicated intra-abdominal infections, UTIs.
Women are more likely to be symptomatic, have greater odds of frequent, severe acute exacerbations.
Individuals with HDHP more likely to report forgoing care due to costs, cost-related nonadherence.